XML 29 R14.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Balance Sheet Account Details | 12 Months Ended
--- | ---
Dec. 31, 2018
Other Balance Sheet Details [Abstract] |
Balance Sheet Account Details | Balance Sheet Account DetailsShort-term Investments The following table summarizes the various investment categories at December 31, 2018 and 2017 (in thousands):
| Cost |  | Gross unrealized gains |  | Gross unrealized losses |  | Estimated fair value
December 31, 2018 |  |  |  |  |  |  |
Short-term investments |  |  |  |  |  |  |
Bank deposits | $ | 311,066 |  | $ | 26 |  | $ | (29) |  | $ | 311,063
Corporate bonds | 53,223 |  | 1 |  | (45) |  | 53,179
Corporate equity securities | 135 |  | 1,191 |  | — |  | 1,326
Commercial paper | 225,731 |  | 8 |  | (76) |  | 225,663
U.S. Government bonds | 7,982 |  | — |  | (9) |  | 7,973
Municipal bonds | 2,017 |  | — |  | (4) |  | 2,013
| $ | 600,154 |  | $ | 1,226 |  | $ | (163) |  | $ | 601,217
December 31, 2017 |  |  |  |  |  |  |
Short-term investments |  |  |  |  |  |  |
Bank deposits | $ | 80,095 |  | $ | 6 |  | $ | (42) |  | $ | 80,059
Corporate bonds | 55,335 |  | — |  | (96) |  | 55,239
Corporate equity securities | 207 |  | 1689 |  | — |  | 1,896
Commercial paper | 27,933 |  | — |  | (20) |  | 27,913
Agency bonds | 4,991 |  | — |  | (1) |  | 4,990
U.S. Government bonds | 8,939 |  | — |  | (10) |  | 8,929
Municipal bonds | 2,028 |  | — |  | (13) |  | 2,015
| $ | 179,528 |  | $ | 1,695 |  | $ | (182) |  | $ | 181,041
Other current assets consist of the following (in thousands):
| December 31, |  |
| 2018 |  | 2017
Restricted cash | $ | 2,616 |  | $ | —
Investment in Viking warrants | 9,257 |  | —
Other | 8,545 |  | 1,514
| $ | 20,418 |  | $ | 1,514
Property and equipment is stated at cost and consists of the following (in thousands):
| December 31, |  |
| 2018 |  | 2017
Lab and office equipment | $ | 4,183 |  | $ | 3,460
Leasehold improvements | 2,418 |  | 1,917
Computer equipment and software | 936 |  | 697
| 7,537 |  | 6,074
Less accumulated depreciation and amortization | (2,165) |  | (1,862)
| $ | 5,372 |  | $ | 4,212
Depreciation of equipment is computed using the straight-line method over the estimated useful lives of the assets which range from three to ten years. Leasehold improvements are amortized using the straight-line method over their estimated useful lives or their related lease term, whichever is shorter. Depreciation expense of $0.9 million, $0.4 million, and $0.2 million was recognized for the years ended December 31, 2018, 2017, and 2016, respectively, and is included in operating expenses. Goodwill and identifiable intangible assets consist of the following (in thousands):
| December 31, |  |
| 2018 |  | 2017
Indefinite lived intangible assets |  |  |
IPR&D | $ | — |  | $ | 7,923
Goodwill | 86,646 |  | 85,959
Definite lived intangible assets |  |  |
Complete technology | 235,413 |  | 222,900
Less: Accumulated amortization | (35,070) |  | (23,301)
Trade name | 2,642 |  | 2,642
Less: Accumulated amortization | (1,048) |  | (916)
Customer relationships | 29,600 |  | 29,600
Less: Accumulated amortization | (11,744) |  | (10,264)
Total goodwill and other identifiable intangible assets, net | $ | 306,439 |  | $ | 314,543
Amortization of finite lived intangible assets is computed using the straight-line method over the estimated useful life of the asset of 20 years. Amortization expense of $15.8 million, $11.3 million, and $10.6 million was recognized for the years ended December 31, 2018 and 2017, and 2016, respectively. Estimated amortization expense for the years ending December 31, 2018 through 2023 is $13.6 million per year. For each of the years ended December 31, 2018, 2017, and 2016, there was no impairment of intangible assets with finite lives. Accrued liabilities consist of the following (in thousands):
| December 31, |  |
| 2018 |  | 2017
Compensation | $ | 4,045 |  | $ | 4,085
Legal | 942 |  | 430
Amounts owed to former licensees | 428 |  | 396
Royalties owed to third parties | 1,025 |  | 954
Payments due to broker for share repurchases | 4,613 |  | —
Return reserve | 3,590 |  | —
Restructuring | 1,093 |  | —
Other | 3,464 |  | 1,512
| $ | 19,200 |  | $ | 7,377
Contingent liabilities: In connection with the acquisition of CyDex in January 2011, we issued a series of CVRs and also assumed certain contingent liabilities. We may be required to make additional payments upon achievement of certain clinical and regulatory milestones to the CyDex shareholders and former license holders. We paid CyDex shareholders, through 2016, 20% of all CyDex-related revenue, but only to the extent that, and beginning only when, CyDex-related revenue for the year exceeds $15.0 million; plus an additional 10% of all CyDex-related revenue recognized during such year, but only to the extent, and beginning only when aggregate CyDex-related revenue for such year exceeds $35.0 million. In connection with the acquisition of Metabasis in January 2010, we entered into four CVR agreements with Metabasis shareholders. The CVRs entitle the holders to cash payments as frequently as every six months as proceeds are received by us upon the sale or licensing of any of the Metabasis drug development programs and upon the achievement of specified milestones. The following table summarizes contingent liabilities as of December 2018 and 2017 (in thousands):
| December 31, 2016 | Payments | Fair Value Adjustment |  | Additions | December 31, 2017 | Payments | Fair Value Adjustment | December 31, 2018
Cydex | $ | 6,600 | $ | (5,000) | $ | — |  | $ | — | $ | 1,600 | $ | (25) | $ | (1,050) | $ | 525
Metabasis | $ | 1,500 | $ | — | $ | 2,500 |  | $ | — | $ | 4,000 | $ | (3,900) | $ | 5,400 | $ | 5,500
Crystal | $ | — | $ | — | $ | — |  | $ | 8,400 | $ | 8,400 | $ | (1,000) | $ | (924) | $ | 6,476
Total | $ | 8,100 | $ | (5,000) | $ | 2,500 |  | $ | 8,400 | $ | 14,000 | $ | (4,925) | $ | 3,426 | $ | 12,501

X
- Definition Other Balance Sheet Details [Abstract] + References No definition available. + Details
Name: | lgnd_OtherBalanceSheetDetailsAbstract
Namespace Prefix: | lgnd_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -URI http://asc.fasb.org/topic&trid=2122208 + Details
Name: | us-gaap_SupplementalBalanceSheetDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration